AstraZeneca (Moventig) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

AstraZeneca (Moventig) General Information

Description

Drug for opioid-induced constipation (OIC) treatment. The portfolio consists of the rights to sell and develop Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • 2 Kingdom Street
  • London W2 6BD
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AstraZeneca (Moventig) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AstraZeneca (Moventig)‘s full profile, request access.

Request a free trial

AstraZeneca (Moventig) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AstraZeneca (Moventig)‘s full profile, request access.

Request a free trial